1. Scrip
  2. >>Conferences

Roche’s First Anti-TIGIT Data Support Dual Checkpoint Inhibition Strategy

 
• By Mandy Jackson

Tiragolumab plus Tecentriq increased response rates versus Tecentriq alone in a Phase II study, with the greatest benefit in PD-L1-high NSCLC. The combination regimen already is being test in Phase III.

Lungs operation puzzle concept: hands of surgeon with surgical instruments (tools) perform lungs surgery as a result of respiratory disease, pneumonia, tuberculosis, bronchitis, asthma, lung abscess
Tiragolumab plus Tecentriq worked best in PD-L1 high NSCLC • Source: Shutterstock

The first public data disclosure for Roche’s anti-TIGIT antibody tiragolumab in combination with the company’s PD-L1 inhibitor Tecentriq (atezolizumab) in first-line metastatic non-small cell lung cancer (NSCLC) showed improved response rates versus Tecentriq alone – including a notable improvement in high PD-L1-expressing tumors – and without adding significant toxicity.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

More from Conferences